Braeburn Pharmaceuticals, Inc. (“Braeburn”) and Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company has announced that Knight’s New Drug Submission (NDS) has been accepted for review by Health Canada for PROBUPHINE® (buprenorphine subdermal implant) for the treatment of opioid drug dependence.
“Probuphine is a unique and innovative product that has the potential to address an important unmet need for opioid dependent patients,” said Jonathan Ross Goodman, Chief Executive Officer of Knight. “With Probuphine, Knight is continuing to advance its portfolio of opioid supportive therapeutics, which includes Movantik®, a product for opioid-induced constipation we in-licensed from AstraZeneca and began commercializing in March of this year.”
“Opioid addiction is an overwhelming public health epidemic in North America. This is another important milestone for Probuphine, an innovative treatment approach with the potential to reduce the risks of diversion, abuse and accidental pediatric exposure,” said Mike Derkacz, President and CEO of Braeburn. “We look forward to working with Knight and Health Canada to bring this important treatment option to Canadian patients.”
Knight and Braeburn signed an exclusive distribution and sublicense agreement in February 2016 granting Knight the exclusive right to distribute Probuphine in Canada.